These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 10954006)

  • 1. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension.
    Devereux RB; Roman MJ; Palmieri V; Okin PM; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Wachtell K; Dahlöf B
    J Hypertens; 2000 Aug; 18(8):1129-38. PubMed ID: 10954006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
    Devereux RB; Palmieri V; Liu JE; Wachtell K; Bella JN; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
    J Hypertens; 2002 Jul; 20(7):1445-50. PubMed ID: 12131543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.
    Palmieri V; Wachtell K; Gerdts E; Bella JN; Papademetriou V; Tuxen C; Nieminen MS; Dahlöf B; de Simone G; Devereux RB
    Am Heart J; 2001 May; 141(5):784-91. PubMed ID: 11320367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint.
    Wachtell K; Rokkedal J; Bella JN; Aalto T; Dahlöf B; Smith G; Roman MJ; Ibsen H; Aurigemma GP; Devereux RB
    Am J Cardiol; 2001 Jan; 87(1):54-60. PubMed ID: 11137834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention For Endpoint Reduction in Hypertension Study.
    Bella JN; Wachtell K; Palmieri V; Liebson PR; Gerdts E; Ylitalo A; Koren MJ; Pedersen OL; Rokkedal J; Dahlöf B; Roman MJ; Devereux RB
    J Hypertens; 2001 Jan; 19(1):127-34. PubMed ID: 11204292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.
    Bang CN; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Roman MJ; Køber L; Wachtell K; Devereux RB
    J Hypertens; 2013 Oct; 31(10):2060-8. PubMed ID: 23838656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Wachtell K; Dahlöf B; Rokkedal J; Papademetriou V; Nieminen MS; Smith G; Gerdts E; Boman K; Bella JN; Devereux RB
    Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study.
    Narayan P; Papademetriou V; Wachtell K; Gerdts E; Boman K; Nieminen MS; de Simone G; Dahlöf B; Fyhrquist F; Hoieggen A; Devereux RB
    Hypertension; 2006 May; 47(5):868-73. PubMed ID: 16567586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
    Palmieri V; Okin PM; de Simone G; Bella JN; Wachtell K; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
    J Hypertens; 2007 May; 25(5):1079-85. PubMed ID: 17414673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
    Oikarinen L; Nieminen MS; Toivonen L; Viitasalo M; Wachtell K; Papademetriou V; Jern S; Dahlöf B; Devereux RB; Okin PM;
    Am Heart J; 2003 May; 145(5):919-25. PubMed ID: 12766755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
    Wachtell K; Bella JN; Rokkedal J; Palmieri V; Papademetriou V; Dahlöf B; Aalto T; Gerdts E; Devereux RB
    Circulation; 2002 Mar; 105(9):1071-6. PubMed ID: 11877357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
    Bang CN; Gerdts E; Aurigemma GP; Boman K; de Simone G; Dahlöf B; Køber L; Wachtell K; Devereux RB
    Circ Cardiovasc Imaging; 2014 May; 7(3):422-9. PubMed ID: 24723582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy.
    Biederman RW; Doyle M; Young AA; Devereux RB; Kortright E; Perry G; Bella JN; Oparil S; Calhoun D; Pohost GM; Dell'Italia LJ
    Hypertension; 2008 Aug; 52(2):279-86. PubMed ID: 18606908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).
    Gerdts E; Cramariuc D; de Simone G; Wachtell K; Dahlöf B; Devereux RB
    Eur J Echocardiogr; 2008 Nov; 9(6):809-15. PubMed ID: 18490279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study.
    Devereux RB; Bang CN; Roman MJ; Palmieri V; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Wachtell K; Hille DA; Dahlöf B
    Hypertension; 2015 Nov; 66(5):945-53. PubMed ID: 26418019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Dahlöf B
    Hypertension; 2000 Nov; 36(5):766-73. PubMed ID: 11082141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender differences in systolic left ventricular function in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).
    Gerdts E; Zabalgoitia M; Björnstad H; Svendsen TL; Devereux RB
    Am J Cardiol; 2001 Apr; 87(8):980-3; A4. PubMed ID: 11305990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study.
    Devereux RB; Bella J; Boman K; Gerdts E; Nieminen MS; Rokkedal J; Papademetriou V; Wachtell K; Wright J; Paranicas M; Okin PM; Roman MJ; Smith G; Dahlöf B
    Blood Press; 2001; 10(2):74-82. PubMed ID: 11467763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint.
    Wachtell K; Smith G; Gerdts E; Dahlöf B; Nieminen MS; Papademetriou V; Bella JN; Ibsen H; Rokkedal J; Devereux RB
    Am J Cardiol; 2000 Feb; 85(4):466-72. PubMed ID: 10728952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.